The widespread reduction in internal R&D spending does not signal a retreat from innovation. Instead, companies are redirecting capital towards external opportunities, evidenced by a recent surge in multi-billion dollar M&A 'bolt-on' deals. This represents a strategic shift from building in-house to buying external assets.
Despite familiar names topping the rankings, R&D spending is down across most of big pharma, with major players like Bristol Myers Squibb, Pfizer, and Merck all reducing budgets. This marks a significant reversal after three decades of consecutive increases in industry-wide drug development pipelines.
Eli Lilly is leveraging its massive GLP-1 drug revenue for a long-term strategic play. Instead of just acquiring single assets, the company is investing in global innovation hubs, supercomputing with NVIDIA, and incubators to build a sustainable innovation backbone, aiming to avoid typical patent cliff-driven downturns.
While Merck's headline R&D budget dropped 12%, this was primarily due to a lack of large M&A deals that inflated the prior year's figure. Beneath the surface, the company actually increased spending on its core mission: discovery research, early drug development, and clinical development, signaling a continued commitment to internal innovation.